These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26535615)

  • 21. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urothelial cancers: using biology to improve outcomes.
    Pezaro C; Liew MS; Davis ID
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [50 years of systemic therapy of urinary bladder cancer].
    Retz M; von Amsberg G; Horn T; Gschwend JE; Maisch P
    Aktuelle Urol; 2019 Aug; 50(4):358-365. PubMed ID: 31242517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advanced bladder cancer : From chemo- to immunotherapy].
    Horn T; Krege S; Retz M
    Urologe A; 2018 Jun; 57(6):686-692. PubMed ID: 29637216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
    Sonpavde G; Pond GR; Rosenberg JE; Choueiri TK; Bellmunt J; Regazzi AM; Mullane SA; Necchi A; Raggi D; Lee JL; Lee S; Simpson J; Derleth CL; Lin SW; Bajorin DF
    Clin Genitourin Cancer; 2018 Aug; 16(4):e961-e967. PubMed ID: 29706503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted agents in second-line bladder cancer therapy.
    Gerullis H; Otto T; Ecke TH
    Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma.
    J Pelletier D; O'Donnell M; Stone MS; Liu V
    J Cutan Pathol; 2018 Jun; 45(6):453-457. PubMed ID: 29484689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Montazeri K; Sonpavde G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
    Aragon-Ching JB; Trump DL
    Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 33. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
    Mollica V; Maggio I; Lopez-Beltran A; Montironi R; Cimadamore A; Cheng L; Rizzo A; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Massari F
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):755-763. PubMed ID: 32757789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of everolimus in metastatic urothelial cancer.
    Smith AB; Pruthi RS
    BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903
    [No Abstract]   [Full Text] [Related]  

  • 37. Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Santini D; Banna GL; Buti S; Isella L; Stellato M; Roberto M; Iacovelli R
    Curr Oncol Rep; 2023 Nov; 25(11):1345-1362. PubMed ID: 37855848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avelumab in locally advanced or metastatic urothelial carcinoma.
    Jackson-Spence F; Szabados B; Toms C; Yang YH; Sng C; Powles T
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):135-140. PubMed ID: 35015593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.
    Uccello M; Adeleke S; Moschetta M; Ghose A; Boussios S
    Ann Palliat Med; 2023 Nov; 12(6):1345-1354. PubMed ID: 37303213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of metastatic bladder cancer.
    Yagoda A
    Cancer; 1980 Apr; 45(7 Suppl):1879-88. PubMed ID: 7189443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.